Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 24 clinical trials
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian Primary Peritoneal or Fallopian Tube Cancer LANCE Trial

This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant chemotherapy). MIS is a surgical procedure that uses small incision(s) and is intended to produce minimal blood …

  • 26 Jan, 2021
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune …

serous adenocarcinoma
primary tumor
  • 10 May, 2022
  • 182 locations
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy

The purpose of this study is to understand the metabolism of cancers involving the kidney, including renal cell carcinomas and urothelial cell carcinomas, and how kidney cancers use different types of fuel to support tumor growth. This study uses specially labeled nutrient tracers of compounds normally found circulating in the …

Accepts healthy volunteers
  • 24 Nov, 2021
  • 1 location
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial enrolls participants for …

ovarian epithelial carcinoma
desmoid tumor
neuroendocrine tumor
  • 11 May, 2022
  • 767 locations
Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)

This is a phase II non-randomized, multi-center study. The primary end point of this study is the objective response rate (ORR) at 24 weeks, using response evaluation criteria for solid tumors (RECIST) 1.1 criteria, for the combination therapy of continuous daily oral lenvatinib with three-weekly intravenous pembrolizumab in patients with …

measurable disease
combination therapy
  • 28 Oct, 2021
  • 1 location
Etigilimab and Nivolumab for the Treatment of Platinum-Resistant Recurrent Clear Cell Ovarian Primary Peritoneal or Fallopian Tube Cancer

This phase II trial the side effects and possible benefits of etigilimab and nivolumab in treating patients with platinum-resistant clear cell ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent). Immunotherapy with monoclonal antibodies, such as etigilimab and nivolumab, may help the body's immune system attack the …

  • 01 Dec, 2021
  • 1 location
Onapristone and Anastrozole in Refractory Estrogen and Progesterone Positive Endometrial Cancer

This phase II trial studies the effect of onapristone and anastrozole in treating patients with hormone receptor positive endometrial cancer that has not responded to previous treatment (refractory). Progesterone and estrogen are hormones that can cause the growth of endometrial cancer cells. Onapristone blocks the use of progesterone by the …

endocrine therapy
serous adenocarcinoma
  • 12 Jun, 2021
  • 2 locations
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

This clinical trial evaluates the effect of tislelizumab in treating patients with mismatch repair deficient endometrial cancer that has come back (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing DNA errors and damage. Mismatch repair deficient tumors (dMMR) may have difficulty repairing DNA mutations …

  • 23 Apr, 2022
  • 1 location
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients

MAMOC is a multicenter, randomized, placebo controlled, double blind study including BRCA negative patients with histologically confirmed, advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIGO classification) high grade serous or high grade endometrioid (based on local histopathological findings) ovarian cancer, fallopian tube cancer, primary peritoneal cancer …

fallopian tube
cancer of the ovary
  • 12 Sep, 2021
  • 23 locations
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

This phase II trial compares how well nivolumab with or without ipilimumab works to shrink cancer masses and prevent additional growth in patients with deficient mismatch repair system (MMR) endometrial cancer that has come back after a period of improvement (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system …

  • 12 May, 2022
  • 2 locations